Menu ×

HEALTHCARE & PHARMACEUTICAL

HIV Drug/Medicine Market Segmentation by Medication Class {Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Protease Inhibitors (PIs), Entry Inhibitors, and HIV Integrase Strand Transfer Inhibitors}; and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others) – Global Demand Analysis & Opportunity Outlook 2031

  • Report ID: 162
  • Text Size:

Extensive insights into the Growth of HIV Drug/Medicine Market amidst COVID-19

Get the detailed impact analysis of COVID-19 that has disrupted the entire world and affected many industries.

Request Insights


IN THE NEWS

  • March 23, 2020: Gilead affirms that its supply chain is resilient even in the pandemic and does not see shortages of HIV treatment or prevention medicines in the future.

  • December 05, 2019: ViiV Healthcare, which is majorly owned by GSK, completed the submission of a New Drug Application (NDA) to the US Food and Drug Administration seeking approval for first-in-class attachment treatment of HIV-1 name Fostemsavir.

Global HIV Drug/Medicine Market Highlights Over 2022-2031 

The global HIV drug/medicine market is estimated to garner notable CAGR over the forecast period, i.e., 2022 – 2031. The growth of the market can be attributed to prevailing cases of acquired immune deficiency syndrome (AIDS). AIDS is caused by the transmission of a virus named human immunodeficiency virus (HIV). The data released by World Health Organisation states that in 2020, there were 1.5 million people who acquired HIV, and 680,000 people died from HIV-related causes. WHO also claims that in 2020 there were 37.7 million people who are living with AIDS. On the back of emerging cases of AIDS, the global HIV drug/medicine market is expected to grow during the forecast period. Furthermore, the governments are raising expenditure for the prevention and treatment of the disease. According to a report released by Joint United Nations Programme on HIV/AIDS (UNAIDS), the availability of international and domestic resources for the prevention and treatment of AIDS reached USD 21.5 million by the end of 2020. On account of the availability of a humongous budget for the treatment of AIDS, the global HIV drug/medicine market is projected to grow during the forecast period. Furthermore, the pro-active participation from all over the world to eliminate AIDS is remarkable. The World Health Organization promulgates 1st December as World AIDS Day to spread awareness about the prevention and treatment of the disease. The global HIV drug/medicine market is estimated to witness significant growth during the forecast period on account of the rising awareness amongst the people.

HIV Drug/Medicine Market

Get more information on this report: Download Sample PDF

The market is segmented by distribution channel into hospital pharmacies, retail pharmacies, online pharmacies, and others. Out of which, the hospital pharmacies sub-segment is anticipated to hold the largest share in the global HIV drug/medicine market during the forecast period on account of the growing number of HIV patients. A large number of HIV patients get admitted to hospitals is estimated to boost the market growth.  

Major Macro-Economic Indicators Impacting the Market Growth

Healthcare Expenditure per Capita, (USD), 2015-2018

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Global HIV Drug/Medicine Market Regional Synopsis

Regionally, the global HIV drug/medicine market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. The market in North America region is estimated to witness noteworthy growth over the forecast period on the back of the presence of an ultra-modern healthcare system. Furthermore, countries such as the USA are making people aware of the prevention and treatment of AIDS. The data released by the American Psychological Association states that 10th April is celebrated as National Youth HIV and AIDS Awareness Day. This event is celebrated to raise awareness amongst youth regarding the treatment of AIDS.

Furthermore, the global HIV drug/medicine market is expected to grow during the forecast period in the Asia Pacific region owing to a large number of patients in the region. According to the data released by UNAIDS in 2020, there were 5.8 million people living with HIV in the APAC region. On the back of the escalating number of HIV patients in the region, the global HIV drug/medicine market is projected to grow during the forecast period. Furthermore, the governments in the region are allotting a plethora of budgets for the prevention and treatment of HIV.

HIV Drug/Medicine Market Share

Get more information on this report: Download Sample PDF

The global HIV drug/medicine market is further classified on the basis of region as follows: 

  • North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook 

  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook 

  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y Growth Market Players Analysis & Opportunity Outlook 

  • Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook 

  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of the Middle East and Africa) Market size, Y-O-Y Growth Market Players Analysis & Opportunity Outlook 

Market Segmentation 

Our in-depth analysis of the global HIV drug/medicine market includes the following segments:  

By Medication Class

  • Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
  • Multi-Class Combination Drugs
  • Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
  • Protease Inhibitors (PIs)
  • Entry Inhibitors
  • HIV Integrase Strand Transfer Inhibitors

By Distribution Channel 

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Growth Drivers  

  • Surging Cases of Cancer Worldwide
  • Rising Initiatives by the Governments

Challenges 

  • Lack of Awareness Regarding the Treatment

Top Featured Companies Dominating the Market 

  • Merck & Co., Inc.
    • Company Overview 
    • Business Strategy 
    • Key Product Offerings 
    • Financial Performance 
    • Key Performance Indicators 
    • Risk Analysis 
    • Recent Development 
    • Regional Presence 
    • SWOT Analysis 
  • Boehringer Ingelheim International GmbH
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc.
  • F. Hoffmann-La Roche Ltd.
  • Cipla Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • Janssen Global Services, LLC
  • Mylan N.V.
  • AbbVie Inc. 

FREQUENTLY ASKED QUESTIONS


Related Reports


Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved